Peroxisome proliferator-activated receptors as targets to treat metabolic diseases: Focus on the adipose tissue, liver, and pancreas

Primer Autor
Souza-Tavares, Henrique
Co-autores
Miranda, Carolline Santos
Vasques-Monteiro, Isabela Macedo Lopes
Sandoval, Cristian
Santana-Oliveira, Daiana Araujo
Silva-Veiga, Flavia Maria
Fernandes-da-Silva, Aline
Souza-Mello, Vanessa
Título
Peroxisome proliferator-activated receptors as targets to treat metabolic diseases: Focus on the adipose tissue, liver, and pancreas
Editorial
BAISHIDENG PUBLISHING GROUP INC
Revista
WORLD JOURNAL OF GASTROENTEROLOGY
Lenguaje
en
Resumen
The world is experiencing reflections of the intersection of two pandemics: Obesity and coronavirus disease 2019. The prevalence of obesity has tripled since 1975 worldwide, representing substantial public health costs due to its comorbidities. The adipose tissue is the initial site of obesity impairments. During excessive energy intake, it undergoes hyperplasia and hypertrophy until overt inflammation and insulin resistance turn adipocytes into dysfunctional cells that send lipotoxic signals to other organs. The pancreas is one of the organs most affected by obesity. Once lipotoxicity becomes chronic, there is an increase in insulin secretion by pancreatic beta cells, a surrogate for type 2 diabetes mellitus (T2DM). These alterations threaten the survival of the pancreatic islets, which tend to become dysfunctional, reaching exhaustion in the long term. As for the liver, lipotoxicity favors lipogenesis and impairs beta-oxidation, resulting in hepatic steatosis. This silent disease affects around 30% of the worldwide population and can evolve into end-stage liver disease. Although therapy for hepatic steatosis remains to be defined, peroxisome proliferator-activated receptors (PPARs) activation copes with T2DM management. Peroxisome PPARs are transcription factors found at the intersection of several metabolic pathways, leading to insulin resistance relief, improved thermogenesis, and expressive hepatic steatosis mitigation by increasing mitochondrial beta-oxidation. This review aimed to update the potential of PPAR agonists as targets to treat metabolic diseases, focusing on adipose tissue plasticity and hepatic and pancreatic remodeling.
Fecha Publicación
2023
Tipo de Recurso
artículo de revisión
doi
10.3748/wjg.v29.i26.4136
Formato Recurso
PDF
Palabras Claves
Obesity
Insulin resistance
Peroxisome proliferator-activated receptors
Pancreas
Hepatic steatosis
Adipose tissue
Ubicación del archivo
Categoría OCDE
Gastroenterología y Hepatología
Materias
Obesidad
Resistencia a la insulina
Receptores activados por proliferadores de peroxisomas
Páncreas
Esteatosis hepática
Tejido adiposo
Página de inicio (Recomendado-único)
4136.0
Página final (Recomendado-único)
4155
Identificador del recurso (Mandatado-único)
artículo de revisión
Versión del recurso (Recomendado-único)
versión publicada
License
CC BY-NC 4.0
Condición de la licencia (Recomendado-repetible)
CC BY-NC 4.0
Derechos de acceso
acceso abierto
Access Rights
acceso abierto
Id de Web of Science
WOS:001032642100003
ISSN
1007-9327
Tipo de ruta
verde# dorado
Categoría WOS
Gastroenterología y Hepatología
Referencia del Financiador (Mandatado si es aplicable-repetible)
CNPQ 303785/2020-9
FAPERJ E-26/200.984/2022
Revisa las metricas alternativas de Almetrics
Revisa las citaciones de Dimensions